



Universiteit
Leiden
The Netherlands

Novel targets in the liver to treat cardiometabolic diseases

Ge, X.

Citation

Ge, X. (2026, January 15). *Novel targets in the liver to treat cardiometabolic diseases*. Retrieved from <https://hdl.handle.net/1887/4286936>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4286936>

Note: To cite this publication please use the final published version (if applicable).

Novel Targets in the Liver to Treat Cardiometabolic Diseases

Xiaoke Ge

Novel Targets in the Liver to Treat Cardiometabolic Diseases

©2026, Xiaoke Ge

Cover design: Xiaoke Ge & Zhixiong Ying

Layout design: Xiaoke Ge

Printing: ProefschriftMaken

ISBN: 978-94-6534-098-2

The work described in this thesis was performed at the Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands, and at the Einthoven Laboratory for Experimental Vascular Medicine, Leiden, The Netherlands.

All rights are reserved. No part of this thesis may be reproduced, stored, or transmitted in any form or by any means without permission in writing from the author.

Novel Targets in the Liver to Treat Cardiometabolic Diseases

Proefschrift

ter verkrijging van

de graad van doctor aan de Universiteit Leiden,

op gezag van rector magnificus prof.dr.ir. H. Bijl,

volgens besluit van het college voor promoties

te verdedigen op donderdag 15 januari 2026

klokke 14:30 uur

door

Xiaoke Ge

geboren te Anhui, China

in 1992

Promotoren

Prof. dr. P.C.N. Rensen

Prof. dr. Y. Wang (Xi'an Jiaotong University, Xi'an, Shaanxi Province, China)

Copromotor

Dr. M. Schönke

Leden promotiecommissie

Prof. dr. K. Willems van Dijk

Prof. dr. I. Bot (Leiden University/Leiden Academic Center for Drug Research)

Prof. dr. N. Zelcer (Amsterdam University Medical Center)

Prof. dr. R. Shiri-Sverdlov (Maastricht University)

Table of contents

Chapter 1	General introduction and outline	7
Chapter 2	Inhibition of DHCR24 activates LXR α to ameliorate hepatic steatosis and inflammation	35
Chapter 3	DHCR24 inhibitor SH42 increases desmosterol without preventing atherosclerosis development in mice	67
Chapter 4	A rare gain of function variant of hepatic lipase attenuates hypercholesterolemia and atherosclerosis in mice via an LDL receptor-independent mechanism	97
Chapter 5	Hepatocyte-specific disruption of Abca6 increases non-HDL cholesterol and aggravates atherosclerosis by attenuating LDL receptor-mediated cholesterol clearance	127
Chapter 6	General discussion and future perspectives	173
Chapter 7		193
	Summary	195
	Samenvatting	199
	摘要	203
	List of publications	205
	Curriculum Vitae	207
	Acknowledgments	209